Dialog Box

Loading...

Table of Targeted Therapies

Targeted therapies are medicines that block the growth and spread of lymphoma by interfering with specific molecules that are involved in the growth, progression and spread of lymphoma.

The development of targeted therapies requires the identification of good cell molecular targets that play a role in lymphoma cell growth and survival. One way to look at this is to identify good molecular targets by comparing the amounts of individual proteins in lymphoma cells with those in normal cells. Proteins that are present in lymphoma cells but not in normal cells are potential targets, especially if they are known to be involved in lymphoma cell growth or survival.

Another approach to identify potential target cells is to determine whether the lymphoma cells produce mutated proteins mutated proteins that drive the progression of lymphoma drive the progression of the lymphoma.

Once a target protein has been identified the next step is to develop a therapy that interferes with the cells ability to grow and survive. The targeted therapy could then work on the lymphoma cells and stop the lymphoma cells from multiplying or even surviving.

The following are examples of targeted therapies and newly approved chemotherapy medicines that are being used. Please ask your specialist doctor if any of these new medicines may be useful for treating your lymphoma subtype.

 

Subtype of lymphoma Medicine
Chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL) Ibrutinib
Idelalisib
Obinutuzumab
Bendamustine
ABT 199 /Venetoclax
Diffuse large B cell lymphoma (DLBCL)
Lenalidomide
 
Follicular lymphoma Idelalisib
Ibrutinib
Lenalidomide
Obinutuzumab
Hodgkin lymphoma

Brentuximab vedotin

Nivolumab

Pembrolizumzb (Keytruda)

Mantle cell lymphoma

Bendamustine Ibrutinib
Ibrutinib
Lenalidomide

Marginal zone lymphoma Ibrutinib
Idelalisib
Lenalidomide
Richter’s syndrome (transformation of B-cell CLL) Ofatumunab
Nivolumab
Ibrutinub
Skin lymphoma Brentuximab vedotin
Romidepsin
Vorinostat
Systemic anaplastic large cell lymphoma Brentuximab vedotin
T-cell lymphoma Belinostat
Brentuximab vedotin
Lenalidomide
Romidepsin
Waldenström’s macroglobulinaemia Ibrutinib
Bortezomib
Idelalisib